PUBLISHER: The Business Research Company | PRODUCT CODE: 1760723
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760723
Strabismus and amblyopia digital therapeutics are software-based medical treatments designed to address visual misalignment and impaired vision through interactive, technology-driven platforms. These therapies are often customized to meet individual needs and progress, fostering visual improvement through consistent use and remote monitoring.
The main types of digital therapeutics for strabismus and amblyopia include both software and hardware. Software-based digital therapeutics are applications specifically developed to treat eye conditions such as strabismus (crossed eyes) and amblyopia (lazy eye). These treatments are commonly used in hospitals, ophthalmic clinics, and other healthcare settings.
The strabismus and amblyopia digital therapeutics market research report is one of a series of new reports from The Business Research Company that provides strabismus and amblyopia digital therapeutics market statistics, including strabismus and amblyopia digital therapeutics industry global market size, regional shares, competitors with a strabismus and amblyopia digital therapeutics market share, detailed strabismus and amblyopia digital therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the strabismus and amblyopia digital therapeutics industry. This strabismus and amblyopia digital therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The strabismus and amblyopia digital therapeutics market size has grown rapidly in recent years. It will grow from $0.55 billion in 2024 to $0.61 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth during the historic period can be attributed to increased research and development in digital eye therapy, government support for healthcare innovation, expanding health insurance coverage for digital health solutions, a growing focus on personalized medicine, and heightened awareness of amblyopia and strabismus.
The strabismus and amblyopia digital therapeutics market size is expected to see rapid growth in the next few years. It will grow to $0.93 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth during the forecast period can be attributed to the rising prevalence of strabismus and amblyopia, growing demand for non-invasive treatments, better access to telemedicine and remote care, an increasing focus on early detection and intervention, and an aging population. Key trends expected during this period include advancements in digital therapeutics technology, improvements in the design of digital apps for eye health, collaboration between technology companies and healthcare providers, the adoption of wearable devices in eye care, and enhancements in digital diagnostics for eye conditions.
The ongoing expansion of telehealth is expected to significantly drive the growth of the strabismus and amblyopia digital therapeutics market. Telehealth involves the use of digital communication technologies to provide healthcare services, consultations, and monitoring remotely, facilitating access to healthcare for patients, particularly in remote or underserved regions. This growth is largely due to the increasing accessibility of healthcare, which enables patients to consult with specialists and receive care without the need for travel or in-person visits. For conditions such as strabismus (misalignment of the eyes) and amblyopia (lazy eye), telehealth enhances digital therapeutics by allowing for continuous remote monitoring and supervision. This is especially beneficial for children, as they can receive consistent, supervised therapy from home. According to Rock Health, a digital health company, 80% of U.S. adults had accessed care via telemedicine as of 2022, an 8 percentage point increase from 72% in 2021. This growing reliance on telehealth services is set to propel the strabismus and amblyopia digital therapeutics market forward.
Leading companies in the strabismus and amblyopia digital therapeutics market are focusing on the development of advanced digital therapy devices that use interactive exercises to improve eye coordination and visual acuity. These devices deliver therapeutic interventions via digital platforms, which are often more engaging and personalized compared to traditional methods. For example, in April 2022, NovaSight, an Israel-based medical device company, announced that its CureSight device received clearance from the U.S. Food and Drug Administration (FDA). CureSight is a digital therapy device designed to treat amblyopia by enhancing visual and stereo acuity through eye-tracking exercises. It trains both eyes to work together by providing interactive visual exercises, aiming to improve collaboration between the eyes. The device was shown to be effective in a multicenter, randomized, controlled study involving 103 children aged 4 to 9, with results demonstrating positive improvements in visual acuity compared to conventional eye patching methods.
In March 2025, Pentec Health Inc., a U.S.-based healthcare company, partnered with Luminopia Inc. to expand the market reach of Luminopia's digital therapeutics for amblyopia and mild strabismus. This strategic partnership aims to enhance the distribution and accessibility of digital therapeutic solutions, improving patient outcomes and making treatments more widely available. Luminopia Inc. is known for its innovative approach to treating amblyopia and strabismus using interactive digital therapeutics, focusing on improving visual function through a more engaging and less invasive approach compared to traditional methods such as patching.
Major players in the strabismus and amblyopia digital therapeutics market are 3M Company, Freedom Scientific Inc., Ocutrx Vision Technologies LLC, Orthoptics Australia Inc., Good-Lite Company, AmblyoPlay, NovaSight Ltd., Luminopia Inc., NeuraSim Health, Bynocs Inc., RevitalVision LLC, Vivid Vision Inc., Binovi Technologies Corp., Wow Vision Therapy, OculoMotor Technologies Inc., Web Vision Therapy, CureSee Vision Therapy, AnteoTech Ltd, VisionBuilder, HTS Vision Therapy Systems.
North America was the largest region in the strabismus and amblyopia digital therapeutics market in 2024. The regions covered in strabismus and amblyopia digital therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the strabismus and amblyopia digital therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The strabismus and amblyopia digital therapeutics market consists of revenues earned by entities by providing services such as digital vision therapy programs, remote patient monitoring, gamified therapeutic exercises, teleconsultation and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The strabismus and amblyopia digital therapeutics market also includes sales of tablet-based therapy kits, eye-tracking devices, therapy management dashboards and vision assessment tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Strabismus And Amblyopia Digital Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on strabismus and amblyopia digital therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for strabismus and amblyopia digital therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The strabismus and amblyopia digital therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.